62 Result(s)
within
Stergios A. Polyzos
-
Article
Letter to the Editor: Comment on: Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers
-
Article
Open AccessRole of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
To summarize published data on the association between glucocorticoids and metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on the possible pathophysiological links and related treatm...
-
Article
Hypogonadism and nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD), recently proposed to be renamed to metabolic dysfunction-associated steatotic liver disease (MASLD), is a major global public health concern, affecting approximately 2...
-
Article
Open AccessDiet, exercise, and supplements: what is their role in the management of the metabolic dysfunction-associated steatotic liver disease in children?
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is the main cause of chronic liver disease in children and adolescents. Indeed, e...
-
Article
Open AccessPartial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver disease
The need to investigate the pathogenesis and treatment of nonalcoholic fatty liver disease (NAFLD) has led to the development of multiple mouse models. The aim of this study was to validate a fast food diet (F...
-
Article
Open AccessAnimal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a prevalent metabolic liver disease closely associated with the epidemics of obesity and type 2 diabetes mellitus (T2DM), but without licensed pharmacological treatm...
-
Article
Open AccessNonalcoholic fatty liver disease test: an external validation cohort
Non-invasive diagnosis of nonalcoholic fatty liver disease (NAFLD) and its advanced phenotypes (e.g., nonalcoholic steatohepatitis; NASH) is a hot research topic. The aim of this report was the validation of a...
-
Article
The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection
To test the hypothesis that during treatment with denosumab osteomorphs and precursors recycle to higher number of osteoclasts with time, we measured TRAcP5b in serum taken 6 months after the last injection in...
-
Article
The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis
The long-term effects of zoledronate treatment in women with postmenopausal osteoporosis who stop denosumab therapy when they become osteopenic are not known. In a prospective, randomized, controlled clinical ...
-
Article
Potential Impact of Helicobacter pylori Infection on Pancreatic Cancer Pathophysiology
-
Article
Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case–control study
The activins-follistatins-inhibins (AFI) hormonal system is considered to regulate muscle and bone mass. We aimed to evaluate AFI in postmenopausal women with an incident hip fracture.
-
Article
Open AccessThe Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
To summarize experimental and clinical evidence on the association between tumor necrosis factor-α (TNF-α) and nonalcoholic fatty liver disease (NAFLD) and discuss potential treatment considerations.
-
Article
Open AccessOsteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
To summarize evidence on the potential involvement of the osteoprotegerin (OPG)/receptor activator of nuclear factor-kappa B (NF-κΒ) ligand (RANKL)/receptor activator of NF-κΒ (RANK) axis in the pathogenesis o...
-
Article
Adverse Outcomes of E-cigarette in Inflammatory Bowel Disease
-
Article
Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease
The cessation of ovarian function is associated with an increase in abdominal adipose tissue, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD), which may contribute to the augmented cardiovascular ri...
-
Article
Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer
-
Article
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
Obesity is closely associated with nonalcoholic fatty liver disease (NAFLD), a highly prevalent disease without any approved medication. The aim of this review was to summarize the evidence on the effect of an...
-
Article
Letter to the Editor Regarding “The Association of Helicobacter pylori, Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomy” by Abeid et al.
-
Article
Nonalcoholic fatty liver disease: lifestyle and quality of life
Nonalcoholic fatty liver disease (NAFLD) is a metabolic disorder whose current rapidly expanding prevalence is causing it to develop into a major global health concern. NAFLD is closely linked to the modern, u...
-
Article
Ιrisin levels in postmenopausal women with an incident hip fracture
